SANUWAVE Health, Inc. (OTCBB: SNWV), an emerging medical technology company focused on the development and commercialization of noninvasive, biological response activating devices in regenerative medicine, today announced that the Company's dermaPACE® device will be the subject of a presentation at Plastic Surgery 2011, the American Society of Plastic Surgeons' National Meeting being held September 23-27 in Denver.
The presentation, titled "Changes in Wound Closure Rate Over Time in a Prospective, Randomized, Double-Blinded, Sham-Controlled, Multicenter Study of Shockwave Technology for the Treatment of Non-Healing Diabetic Foot Ulcers," will take place as part of the Research & Technology Track I on Saturday, September 24 from 1:00 p.m. to 2:00 p.m. Mountain time. The presentation will be delivered by Lawrence Bass, M.D., Clinical Assistant Professor of Plastic Surgery, Department of Plastic Surgery, NYU School of Medicine, and the safety monitor for the recently completed pivotal Phase III, Investigational Device Exemption (IDE) clinical trial of dermaPACE for the treatment of diabetic foot ulcers.
"I am pleased that the dermaPACE clinical trial results have been accepted for presentation at the premier educational event for plastic surgeons and supporting industry in the U.S.," stated Christopher M. Cashman, President and Chief Executive Officer of SANUWAVE. "This event marks the first time that an esteemed national and international audience of plastic surgeons will be exposed to the healing power of PACE® technology to treat diabetic foot ulcers and to the commitment of SANUWAVE to support evidence-based medicine."